Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial

BACKGROUND: In CheckMate 9LA, nivolumab plus ipilimumab with chemotherapy prolonged overall survival (OS) versus chemotherapy regardless of tumor PD-L1 expression or histology. We report updated efficacy and safety in all randomized patients with a minimum 4-year follow-up and an exploratory treatment-switching adjustment analysis in all treated patients who received chemotherapy and subsequent immunotherapy. METHODS: Adults with stage IV/recurrent non-small cell lung cancer (NSCLC), no sensitizing EGFR/ALK alterations, and ECOG performance status

• Carbone, D. P.
• Ciuleanu, T. E.
• Schenker, M.
• Cobo, M.
• Bordenave, S.
• Juan-Vidal, O.
• Menezes, J.
• Reinmuth, N.
• Richardet, E.
• Cheng, Y.
• Mizutani, H.
• Felip, E.
• Zurawski, B.
• Alexandru, A.
• Paz-Ares, L.
• Lu, S.
• John, T.
• Zhang, X.
• Mahmood, J.
• Hu, N.
• De, T.
• Santi, I.
• Penrod, J. R.
• Yuan, Y.
• Lee, A.
• Reck, M.